Targeting calcium channels to block tumor vascularization

Recent Patents on Anti-Cancer Drug Discovery

Volumn 8, Issue 1, 2013, Pages 27-37

  Munaron, Luca ^a   Genova, Tullio ^a   Avanzato, Daniele ^a   Antoniotti, Susanna ^a   Pla, Alessandra Fiorio ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Calcium channels; Endothelial cells; Tumor angiogenesis; Tumor vascularization

Indexed keywords

5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; ANNEXIN; ARACHIDONIC ACID; CALCINEURIN; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL T TYPE; CALCIUM ION; CALCIUM RELEASE ACTIVATED CALCIUM CHANNEL; CALCIUM RELEASE ACTIVATED CALCIUM CHANNEL 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROGEN SULFIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NANOPARTICLE; NITRIC OXIDE; PHOSPHOLIPASE A2; SODIUM CHANNEL NAV1.5; STROMAL INTERACTION MOLECULE 1; TRANSCRIPTION FACTOR NFAT; TRANSIENT RECEPTOR POTENTIAL CHANNEL; TRANSIENT RECEPTOR POTENTIAL CHANNEL 1; TRANSIENT RECEPTOR POTENTIAL CHANNEL 4; TRANSIENT RECEPTOR POTENTIAL CHANNEL 6; TRANSIENT RECEPTOR POTENTIAL CHANNEL A1; TRANSIENT RECEPTOR POTENTIAL CHANNEL M8; VANILLOID RECEPTOR 4; VASCULOTROPIN; VOLTAGE GATED CALCIUM CHANNEL;

BREAST CARCINOMA; CALCIUM CELL LEVEL; CALCIUM CURRENT; CALCIUM SIGNALING; CALCIUM TRANSPORT; CELL HYPOXIA; CELL MEMBRANE; ENDOTHELIUM CELL; GLIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; METASTASIS; NITROSYLATION; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; REVIEW; SHEAR STRESS; STORE OPERATED CALCIUM ENTRY; TUMOR DERIVED ENDOTHELIAL CELL; TUMOR GROWTH; TUMOR VASCULARIZATION;

EID: 84875425846     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574892811308010027     Document Type: Review

References (163)

1. Nilius B, Droogmans G. Ion channels and their functional role in vascular endothelium. Physiol Rev 2001; 81(4): 1415-1459.
2. Di A, Malik AB. TRP channels and the control of vascular function. Curr Opin Pharmacol 2010; 10(2): 127-132.
3. Dietrich A, Kalwa H, Gudermann T. TRPC channels in vascular cell function. Thromb Haemost 2010; 103(2): 262-270.
4. Cahalan MD. Stimulating store-operated Ca(2+) entry. Nat Cell Biol 2009; 11(6): 669-677.
5. Langenkamp E, Molema G. Microvascular endothelial cell heterogeneity: General concepts and pharmacological consequences for anti-angiogenic therapy of cancer. Cell Tissue Res 2009; 335(1): 205-222.
6. Nilius B, Viana F, Droogmans G. Ion channels in vascular endothelium. Annu Rev Physiol 1997; 59: 145-170.
7. Patton AM, Kassis J, Doong H, Kohn EC. Calcium as a molecular target in angiogenesis. Curr Pharm Des 2003; 9(7):543-551.
8. Munaron L, FiorioPla A. Endothelial calcium machinery and angiogenesis: Understanding physiology to interfere with pathology. Curr Med Chem 2009; 16(35): 4691-4703.
9. Yao X, Garland CJ. Recent developments in vascular endothelial cell transient receptor potential channels. Circ Res 2005; 97(9): 853-863.
10. Nilius B. TRP channels in disease. Biochim Biophys Acta 2007; 1772(8): 805-812.
11. Munaron L. Intracellular calcium, endothelial cells and angiogenesis. Recent Pat Anti-Cancer Drug Discov 2006; 1(1): 105-119.
12. 2+entry: A way to control cell proliferation. Curr Med Chem 2004; 11(12): 1533-1543.
13. Munaron L, Tomatis C, FiorioPla A. The secret marriage between calcium and tumor angiogenesis. Technol Cancer Res Treat 2008; 7(4): 335-339.
14. Koch S, Tugues S, Li X, Gualandi L, Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Biochem J 2011; 437(2): 169-183.
15. Ingber, D., Thodeti, C. Methods of modulating angiogenesis via TRPV4. US20110150894 (2011).
16. Everaerts W, Nilius B, Owsianik G. The vanilloid transient receptor potential channel TRPV4: From structure to disease. Prog Biophys Mol Biol 2010; 103(1): 2-17.
17. Lee, N., Chen, J., Feder, J.N., Wu, S., Lee, L.M., Blanar, M.A. TRP channel family member, LTRPC3 polypeptides. US7504481 (2009).
18. Reynolds, M., Polakis, P. Trp-p8 active compounds and therapeutic treatment methods. US7893072 (2011).
19. Tymianski, M., Garman, J.D., Belmares, M.P. Polypeptides for modulating binding of TRP channel proteins and TRP- associated proteins. US20080119412 (2008).
20. Olson, E., Bush, E. Inhibition of TRP channels as a treatment for cardiac hypertrophy and heart failure. US20050182011 (2005).
21. Kwan HY, Huang Y, Yao X. TRP channels in endothelial function and dysfunction. Biochim Biophys Acta 2007; 1772(8): 907-914.
22. Venkatachalam K, Montell C. TRP channels. Annu Rev Biochem 2007; 76: 387-417.
23. Birnbaumer L. The TRPC class of ion channels: A critical review of their roles in slow, sustained increases in intracellular Ca(2+) concentrations. Annu Rev Pharmacol Toxicol 2009; 49: 395-426.
24. Nilius B, Mahieu F, Karashima Y, Voets T. Regulation of TRP channels: A voltage-lipid connection. Biochem Soc Trans 2007; 35(Pt 1): 105-108.
25. Nilius B, Owsianik G, Voets T, Peters JA. Transient receptor potential cation channels in disease. Physiol Rev 2007; 87(1): 165-217.
26. Damann N, Voets T, Nilius B. TRPs in our senses. Curr Biol 2008; 18(18): R880-R889.
27. Watanabe H, Murakami M, Ohba T, Takahashi Y, Ito H. TRP channel and cardiovascular disease. Pharmacol Ther 2008; 118(3): 337-351.
28. Cheng HW, James AF, Foster RR, Hancox JC, Bates DO. VEGF activates receptor-operated cation channels in human microvascular endothelial cells. Arterioscler Thromb Vasc Biol 2006; 26(8): 1768-1776.
29. Pocock TM, Foster RR, Bates DO. Evidence of a role for TRPC channels in VEGF-mediated increased vascular permeability in vivo. Am J Physiol Heart Circ Physiol 2004; 286(3): H1015-H1026.
30. Hamdollah Zadeh MA, Glass CA, Magnussen A, Hancox JC, Bates DO. VEGF-mediated elevated intracellular calcium and angiogenesis in human microvascular endothelial cells in vitro are inhibited by dominant negative TRPC6. Microcirculation 2008; 15(7): 605-614.
31. Ge R, Tai Y, Sun Y, Zhou K, Yang S, Cheng T, et al. Critical role of TRPC6 channels in VEGF-mediated angiogenesis. Cancer Lett 2009; 283(1): 43-51.
32. 2+ entry, endothelial permeability, and angiogenesis. J Biol Chem 2010; 285(43): 33082-33091.
33. Chigurupati S, Venkataraman R, Barrera D, Naganathan A, Madan M, Paul L, et al. Receptor channel TRPC6 is a key mediator of notch-driven glioblastoma growth and invasiveness. Cancer Res 2010; 70(1): 418-427.
34. 2+ entry. Role in signaling increased endothelial permeability. J Biol Chem 2003; 278(35): 33492-33500.
35. 2+ influx and endothelial permeability. Am J Physiol Lung Cell Mol Physiol 2004; 287(6): L1303-L1313.
36. Jho D, Mehta D, Ahmmed G, Gao XP, Tiruppathi C, Broman M, et al. Angiopoietin-1 opposes VEGF-induced increase in endothelial permeability by inhibiting TRPC1-dependent Ca2 influx. Circ Res 2005; 96(12): 1282-1290.
37. Yu PC, Gu SY, Bu JW, Du JL. TRPC1 is essential for in vivo angiogenesis in zebrafish. Circ Res 2010; 106(7): 1221-1232.
38. Antigny F, Girardin N, Frieden M. Transient receptor potential canonical channels are required for in vitro endothelial tube formation. J Biol Chem 2012; 287(8): 5917-5927.
39. Everaerts W, Zhen X, Ghosh D, Vriens J, Gevaert T, Gilbert JP, et al. Inhibition of the cation channel TRPV4 improves bladder function in mice and rats with cyclophosphamide-induced cystitis. Proc Natl Acad Sci USA 2010; 107(44): 19084-19089.
40. Becker D, Blase C, Bereiter-Hahn J, Jendrach M. TRPV4 exhibits a functional role in cell-volume regulation. J Cell Sci 2005; 118(Pt 11): 2435-2440.
41. Hartmannsgruber V, Heyken WT, Kacik M, Kaistha A, Grgic I, Harteneck C, et al. Arterial response to shear stress critically depends on endothelial TRPV4 expression. PLoS ONE 2007; 2(9): e827.
42. Klausen TK, Pagani A, Minassi A, Ech-Chahad A, Prenen J, Owsianik G, et al. Modulation of the transient receptor potential vanilloid channel TRPV4 by 4alpha-phorbol esters: A structure-activity study. J Med Chem 2009; 52(9): 2933-2939.
43. Nilius B, Vriens J, Prenen J, Droogmans G, Voets T. TRPV4 calcium entry channel: A paradigm for gating diversity. Am J Physiol Cell Physiol 2004; 286(2): C195-C205.
44. Nilius B, Watanabe H, Vriens J. The TRPV4 channel: Structure-function relationship and promiscuous gating behaviour. Pflugers Arch 2003; 446(3): 298-303.
45. Vriens J, Watanabe H, Janssens A, Droogmans G, Voets T, Nilius B. Cell swelling, heat, and chemical agonists use distinct pathways for the activation of the cation channel TRPV4. Proc Natl Acad Sci USA 2004; 101(1): 396-401.
46. Thodeti CK, Matthews B, Ravi A, Mammoto A, Ghosh K, Bracha AL, et al. TRPV4 channels mediate cyclic strain-induced endothelial cell reorientation through integrin-to-integrin signaling. Circ Res 2009; 104(9): 1123-1130.
47. Troidl C, Troidl K, Schierling W, Cai WJ, Nef H, Mollmann H, et al. Trpv4 induces collateral vessel growth during regeneration of the arterial circulation. J Cell Mol Med 2009; 13(8B): 2613-2621.
48. Smith, J.W., Axelrod, F., Kridel, S.J. Inhibition of fatty acid synthase by beta-lactones and other compounds for inhibition of cellular proliferation. US7799826 (2010).
49. Meves H. Arachidonic acid and ion channels: An update. Br J Pharmacol 2008; 155(1): 4-16.
50. Munaron L. Shuffling the cards in signal transduction: Calcium, arachidonic acid and mechanosensitivity. WJBC 2011; 2(4): 59.
51. van Rossum DB, Patterson RL. PKC and PLA2: Probing the complexities of the calcium network. Cell Calcium 2009; 45(6): 535-545.
52. Linkous AG, Yazlovitskaya EM, Hallahan DE. Cytosolic phospholipase A2 and lysophospholipids in tumor angiogenesis. J Nat Cancer Inst 2010; 102(18): 1398-1412.
53. FiorioPla A, Ong HL, Cheng KT, Brossa A, Bussolati B, Lockwich T, et al. TRPV4 mediates tumor-derived endothelial cell migration via arachidonic acid-activated actin remodeling. Oncogene 2012; 31(2): 200-212.
54. Tosato G, Segarra M, Salvucci O. Cytosolic phospholipase A2{alpha} and cancer: A role in tumor angiogenesis. J Nat Cancer Inst 2010; 102(18): 1377-1379.
55. Giurdanella G, Motta C, Muriana S, Arena V, Anfuso CD, Lupo G, et al. Cytosolic and calcium-independent phospholipase A(2) mediate glioma-enhanced proangiogenic activity of brain endothelial cells. Microvasc Res 2011; 81(1): 1-17.
56. Patierno, S.R., Manyak, M.J. Non-steroidal anti-inflammatory agent therapy for epithelial cell cancer. US6335321 (2002).
57. Patierno, S.R., Manyak, M.J. Inhibitors of phospholipase A2. US20020151470 (2002).
58. Hallahan, D.E., Yazlovitskaya, E.M. Specific inhibition of cPLA2 enhances the efficacy of radiotherapy. US20080262286 (2008).
59. North S, Moenner M, Bikfalvi A. Recent developments in the regulation of the angiogenic switch by cellular stress factors in tumors. Cancer Lett 2005; 218(1): 1-14.
60. 2+ entry and endothelial hyperpermeability. Circ Res 2008; 102(3): 347-355.
61. Takahashi N, Kuwaki T, Kiyonaka S, Numata T, Kozai D, Mizuno Y, et al. TRPA1 underlies a sensing mechanism for O2. Nat Chem Biol 2011; 7(10): 701-711.
62. + channels. Circ Res 2009; 104(8): 987-994.
63. Andersson DA, Gentry C, Moss S, Bevan S. Transient receptor potential A1 is a sensory receptor for multiple products of oxidative stress. J Neurosci 2008; 28(10): 2485-2494.
64. Trevisani M, Siemens J, Materazzi S, Bautista DM, Nassini R, Campi B, et al. 4-Hydroxynonenal, an endogenous aldehyde, causes pain and neurogenic inflammation through activation of the irritant receptor TRPA1. Proc Natl Acad Sci USA 2007; 104(33): 13519-13524.
65. Bautista DM, Jordt SE, Nikai T, Tsuruda PR, Read AJ, Poblete J, et al. TRPA1 mediates the inflammatory actions of environmental irritants and proalgesic agents. Cell 2006; 124(6): 1269-1282.
66. Bessac BF, Sivula M, von Hehn CA, Escalera J, Cohn L, Jordt SE. TRPA1 is a major oxidant sensor in murine airway sensory neurons. J Clin Invest 2008; 118(5): 1899-1910.
67. Mussunoor S, Murray GI. The role of annexins in tumour development and progression. J Pathol 2008; 216(2): 131-140.
68. Tuszynski GP, Sharma MR, Rothman VL, Sharma MC. Angiostatin binds to tyrosine kinase substrate annexin II through the lysine-binding domain in endothelial cells. Microvasc Res 2002; 64(3): 448-462.
69. Kim J, Hajjar KA. Annexin: A plasminogen-plasminogen activator co-receptor. Front Biosci 2002; 7: d341-d348.
70. Sharma MC, Sharma M. The role of annexin II in angiogenesis and tumor progression: A potential therapeutic target. Curr Pharm Des 2007; 13(35): 3568-3575.
71. Bao H, Jiang M, Zhu M, Sheng F, Ruan J, Ruan C. Overexpression of annexin II affects the proliferation, apoptosis, invasion and production of proangiogenic factors in multiple myeloma. Int J Hematol 2009; 90(2): 177-185.
72. Sharma M, Ownbey RT, Sharma MC. Breast cancer cell surface annexin II induces cell migration and neoangiogenesis via tPA dependent plasmin generation. Exp Mol Pathol 2010; 88(2): 278-286.
73. Zhao S, Huang L, Wu J, Zhang Y, Pan D, Liu X. Vascular endothelial growth factor upregulates expression of annexin A2 in vitro and in a mouse model of ischemic retinopathy. Mol Vis 2009; 15: 1231-1242.
74. Genetos DC, Wong A, Watari S, Yellowley CE. Hypoxia increases annexin A2 expression in osteoblastic cells via VEGF and ERK. Bone 2010; 47(6): 1013-1019.
75. Waisman, D., Kwon, M. Anti-angiogenesis methods, compositions and uses therefor. US7250271 (2007).
76. Jacoby, D.B., Kesavan, K., Sentissi, A., Egan, M.E. Inhibition of angiogenesis. US20110027177 (2011).
77. Park JE, Lee DH, Lee JA, Park SG, Kim NS, Park BC, et al. Annexin A3 is a potential angiogenic mediator. Biochem Biophys Res Commun 2005; 337(4): 1283-1287.
78. Cahill, M., Schrattenholz, A. Annexin A3 for prostate cancer diagnosis. US7732148 (2010).
79. Fischer C, Schneider M, Carmeliet P. Principles and therapeutic implications of angiogenesis, vasculogenesis and arteriogenesis. Handb Exp Pharmacol 2006; (176 Pt 2): 157-212.
80. Pearson JD. Endothelial progenitor cells - hype or hope? J Thromb Haemost 2009; 7(2): 255-262.
81. Sanchez-Hernandez Y, Laforenza U, Bonetti E, Fontana J, Dragoni S, Russo M, et al. Store-operated Ca(2+) entry is expressed in human endothelial progenitor cells. Stem Cells Dev 2010; 19(12): 1967-1981.
82. Kuang CY, Yu Y, Wang K, Qian DH, Den MY, Huang L. Knockdown of transient receptor potential canonical-1 reduces the proliferation and migration of endothelial progenitor cells. Stem Cells Dev 2012; 21(3): 487-496.
83. Vriens J, Appendino G, Nilius B. Pharmacology of vanilloid transient receptor potential cation channels. Mol Pharmacol 2009; 75(6): 1262-1279.
84. Moran MM, McAlexander MA, Bíró T, Szallasi A. Transient receptor potential channels as therapeutic targets. Nat Rev Drug Discov 2011; 10(8): 601-620.
85. Kiyonaka S, Kato K, Nishida M, Mio K, Numaga T, Sawaguchi Y, et al. Selective and direct inhibition of TRPC3 channels underlies biological activities of a pyrazole compound. Proc Natl Acad Sci USA 2009; 106(13): 5400-5405.
86. Abdullaev IF, Bisaillon JM, Potier M, Gonzalez JC, Motiani RK, Trebak M. Stim1 and Orai1 mediate CRAC currents and store-operated calcium entry important for endothelial cell proliferation. Circ Res 2008; 103(11): 1289-1299.
87. 2+ entry and endothelial tube formation. Circ Res 2011; 108(10): 1190-1198.
88. Beech DJ. Orai1 calcium channels in the vasculature. Pflugers Arch 2012; 463(5): 635-647.
89. Xie, Y., Holmqvist, M., Mahiou, J., Ono, M., Sun, L., Chen, S., Zhang, S., Jiang, J., Chimmanamada, D., Fleig, A., Yu, C.-Y. Method for molulating calcium ion-release-activated calcium ion channels. WO2005009954 (2005).
90. Li J, McKeown L, Ojelabi O, Stacey M, Foster R, O'Regan D, et al. Nanomolar potency and selectivity of a Ca(2) release-activated Ca(2) channel inhibitor against store-operated Ca(2) entry and migration of vascular smooth muscle cells. Br J Pharmacol 2011; 164(2): 382-393.
91. Kuo IY-T, Wölfle SE, Hill CE. T-Type calcium channels and vascular function: The new kid on the block? J Physiol 2011; 589(Pt 4): 783-795.
92. 2+ currents in adrenal medulla endothelial cells. Am J Physiol 1999; 276(4 Pt 2): H1313-H1322.
93. Takeda K, Schini V, Stoeckel H. Voltage-activated potassium, but not calcium currents in cultured bovine aortic endothelial cells. Pflugers Arch 1987; 410(4-5): 385-393.
94. Bregestovski PD, Ryan US. Voltage-gated and receptor-mediated ionic currents in the membrane of endothelial cells. J Mol Cell Cardiol 1989; 21 SUPPL. 1: 103-108.
95. Daut J, Mehrke G, Nees S, Newman WH. Passive electrical properties and electrogenic sodium transport of cultured guinea-pig coronary endothelial cells. J Physiol 1988; 402: 237-254.
96. 2+ channels mediate vaso-occlusion of sickled erythrocytes in lung microcirculation. Circ Res 2003; 93(4): 346-353.
97. Bossu JL, Elhamdani A, Feltz A. Voltage-dependent calcium entry in confluent bovine capillary endothelial cells. FEBS Lett 1992; 299(3): 239-242.
98. Martini A, Bruno R, Mazzulla S, Nocita A, Martino G. Angiotensin II regulates endothelial cell migration through calcium influx via T-type calcium channel in human umbilical vein endothelial cells. Acta Physiol (Oxf) 2010; 198(4): 449-455.
99. Miura S, Fujino M, Matsuo Y, Tanigawa H, Saku K. Nifedipine-induced vascular endothelial growth factor secretion from coronary smooth muscle cells promotes endothelial tube formation via the kinase insert domain-containing receptor/fetal liver kinase-1/NO pathway. Hypertens Res 2005; 28(2): 147-153.
100. Bourinet, E., Escoubas, P., Marger, F., Nargeot, J., Lazdunski, M. Identification of novel antagonist toxins of T-type calcium channels for antagonist purposes. US20120040909 (2012).
101. 2+ entry and tumor-derived human endothelial cell migration. Mol Cancer Res 2010; 8(11): 1466-1476.
102. Grosset-fournier, Chantal Catherine. Oligonucleotides inhibiting cellular migration. EP2283870 (2011).
103. 2+ entry is involved in early steps of tumor angiogenesis. Mol Cancer Res 2008; 6(4): 535-545.
104. Antoniotti S, Fattori P, Tomatis C, Pessione E, Munaron L. Arachidonic acid and calcium signals in human breast tumor-derived endothelial cells: A proteomic study. J Recept Signal Transduct Res 2009; 29(5): 257-265.
105. Bussolati B, Grange C, Camussi G. Tumor exploits alternative strategies to achieve vascularization. FASEB J 2011; 25(9): 2874-2882.
106. Croix, B., Seaman, S. Differential gene expression in physiological and pathological angiogenesis. US20110207141 (2011).
107. Raza A, Franklin MJ, Dudek AZ. Pericytes and vessel maturation during tumor angiogenesis and metastasis. Am J Hematol 2010; 85(8): 593-598.
108. Ribatti D, Nico B, Crivellato E. The role of pericytes in angiogenesis. Int J Dev Biol 2011; 55(3): 261-268.
109. Parker BS, Argani P, Cook BP, Liangfeng H, Chartrand SD, Zhang M, et al. Alterations in vascular gene expression in invasive breast carcinoma. Cancer Res 2004; 64(21): 7857-7866.
110. Seaman S, Stevens J, Yang MY, Logsdon D, Graff-Cherry C, St Croix B. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 2007; 11(6): 539-554.
111. Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, et al. Genes expressed in human tumor endothelium. Science 2000; 289(5482): 1197-1202.
112. Bussolati B, Deambrosis I, Russo S, Deregibus M, Camussi G. Altered angiogenesis and survival in human tumor-derived endothelial cells. FASEB J 2003; 17(6): 1159-1161.
113. Bussolati B, Deregibus MC, Camussi G. Characterization of molecular and functional alterations of tumor endothelial cells to design anti-angiogenic strategies. Curr Vasc Pharmacol 2010; 8(2): 220-232.
114. Grange C, Bussolati B, Bruno S, Fonsato V, Sapino A, Camussi G. Isolation and characterization of human breast tumor-derived endothelial cells. Oncol Rep 2006; 15(2): 381-386.
115. Baker, K.P., Ferrara, N., Gerber, H., Gerritsen, M.E., Goddard, A., Godowski, P.J., Gurney, A.L., Hillan, K.J., Marsters, S.A., Pan, J., Paoni, N.F., Stephan, J.-P.F., Watanabe, C.K., Williams, M.P., Wood, W.I., Ye, W. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis. EP2275549 (2011).
116. Cuttitta, F., Martinez, A., Stetler-stevenson, W.G. Target for anti-angiogenesis therapy. US20090048170 (2009).
117. Ip, M.M., Masso-welch, P., Ip, C., Zangani, D. Method for inhibition of angiogenesis and vasculogenesis. US6977271 (2005).
118. Li, J., Shie, J.-l., Laham, R.J. Methods and compositions for treating conditions involving abnormal angiogenesis. US7850959 (2010).
119. Merisko-liversidge, E., Bosch, W.H., Cary, G.G., Pruitt, J., Ryde, T., Jain, R., Walters A. Nanoparticulate compositions of angiogenesis inhibitors. US20100329976 (2010).
120. Leong S, Dvorak HF, Weaver VM, Tlsty TD, Bergers G. Tumor microenvironment and progression. J Surg Oncol 2011; 103(6): 468-474.
121. Chi J-T, Chang HY, Haraldsen G, Jahnsen FL, Troyanskaya OG, Chang DS, et al. Endothelial cell diversity revealed by global expression profiling. Proc Natl Acad Sci USA 2003; 100(19): 10623-10628.
122. Pupo E, FiorioPla A, Avanzato D, Moccia F, Avelino-Cruz JE, Tanzi F, et al. Hydrogen sulfide promotes calcium signals and migration in tumor-derived endothelial cells. Free Radical Bio Med 2011; 51(9): 1765-1773.
123. Veliceasa D, Ivanovic M, Hoepfner FT-S, Thumbikat P, Volpert OV, Smith ND. Transient potential receptor channel 4 controls thrombospondin-1 secretion and angiogenesis in renal cell carcinoma. FEBS J 2007; 274(24): 6365-6377.
124. Muthuppalaniappan, M., Viswanadha, S., Varanasi, K.V., Merikapudi, G.S., Vakkalanka, V. S.S.K. Novel modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer. US20110112058 (2011).
125. Chen YF, Chiu WT, Chen YT, Lin PY, Huang HJ, Chou CY, et al. Calcium store sensor stromal-interaction molecule 1-dependent signaling plays an important role in cervical cancer growth, migration, and angiogenesis. Proc Natl Acad Sci USA 2011; 106(16): 15225-15230.
126. Panner A, Wurster RD. T-type calcium channels and tumor proliferation. Cell Calcium 2006; 40(2): 253-259.
127. Li W, Zhang SL, Wang N, Zhang BB, Li M. Blockade of T-type Ca(2+) channels inhibits human ovarian cancer cell proliferation. Cancer Invest 2011; 29(5): 339-346.
128. 2+ channel in hepatocellular carcinoma cell proliferation. Oncol Rep 2009; 22(5): 1229-1235.
129. Panner A, Cribbs LL, Zainelli GM, Origitano TC, Singh S, Wurster RD. Variation of T-type calcium channel protein expression affects cell division of cultured tumor cells. Cell Calcium 2005; 37(2): 105-119.
130. Petty, H.R., Kindzelski, A.L., Huang, J-B. Anti-metastatic ability of mibefradil and gadolinium. US20060003020 (2006).
131. Gray, L.S., Macdonald, T.L., Haverstick, D.M., Patterson, J.R., Mcclamont, W.F. T Type calcium channel inhibitors. US20090234019 (2009).
132. Shuttleworth TJ. Arachidonic acid, ARC channels, and Orai proteins. Cell Calcium 2009; 45(6): 602-610.
133. FiorioPla A, Ong HL, Cheng KT, Brossa A, Bussolati B, Lockwich T, et al. TRPV4 mediates tumor-derived endothelial cell migration via arachidonic acid-activated actin remodeling. Oncogene 2011; 31(2): 200-212.
134. 2+ signalling--an introduction. Cell Calcium 2009; 45(6): 517-520.
135. Hardie RC. TRP channels and lipids: From Drosophila to mammalian physiology. J Physiol 2007; 578(Pt 1): 9-24.
136. Watanabe H, Vriens J, Prenen J, Droogmans G, Voets T, Nilius B. Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels. Nature 2003; 424(6947): 434-438.
137. Hardie RC. Regulation of TRP channels via lipid second messengers. Annu Rev Physiol 2003; 65: 735-759.
138. Andersson DA, Nash M, Bevan S. Modulation of the cold-activated channel TRPM8 by lysophospholipids and polyunsaturated fatty acids. J Neurosci 2007; 27(12): 3347-3355.
139. Streng T, Axelsson HE, Hedlund P, Andersson DA, Jordt S-E, Bevan S, et al. Distribution and function of the hydrogen sulfide-sensitive TRPA1 ion channel in rat urinary bladder. Eur Urol 2008; 53(2): 391-399.
140. Howe AK. Cross-talk between calcium and protein kinase A in the regulation of cell migration. Curr Opin Cell Biol 2011; 23(5): 554-561.
141. Butt E, Bernhardt M, Smolenski A, Kotsonis P, Fröhlich LG, Sickmann A, et al. Endothelial nitric-oxide synthase (type III) is activated and becomes calcium independent upon phosphorylation by cyclic nucleotide-dependent protein kinases. J Biol Chem 2000; 275(7): 5179-5187.
142. Toro CA, Arias LA, Brauchi S. Sub-cellular distribution and translocation of TRP channels. Curr Pharm Biotechnol 2011; 12(1): 12-23.
143. Ambudkar IS. Trafficking of TRP channels: Determinants of channel function. Handb Exp Pharmacol 2007; (179): 541-557.
144. Planells-Cases R, Ferrer-Montiel A. TRP Channel Trafficking. In: Liedtke WB HS, Eds. TRP Ion Channel Function in Sensory Transduction and Cellular Signaling Cascades. ed. CRC Press: Boca Raton (FL), 2007.
145. 2+ stores stimulates the translocation of vanilloid transient receptor potential 4-C1 heteromeric channels to the plasma membrane. Arterioscler Thromb Vasc Biol 2010; 30(11): 2249-2255.
146. Inoue R, Jian Z, Kawarabayashi Y. Mechanosensitive TRP channels in cardiovascular pathophysiology. Pharmacol Ther 2009; 123(3): 371-385.
147. Su Z, Zhou X, Loukin SH, Haynes WJ, Saimi Y, Kung C. The use of yeast to understand TRP-channel mechanosensitivity. Pflugers Arch 2009; 458(5): 861-867.
148. Yin J, Kuebler WM. Mechanotransduction by TRP channels: General concepts and specific role in the vasculature. Cell Biochem Biophys 2010; 56(1): 1-18.
149. Hamill, O.P., Maroto, R. Mechanosensitive ion channels and methods of use. US20080305520 (2008).
150. Cioffi DL, Barry C, Stevens T. Store-operated calcium entry channels in pulmonary endothelium: The emerging story of TRPCS and Orai1. Adv Exp Med Biol 2010; 661: 137-154.
151. Lockyer, P., Lockyer, J. Methods for detecting calcium ion influx. US20080160536 (2008).
152. Crabtree, G.R., Graef, I., Chen, F. Methods and compositions for modulating angiogenesis. US7323439 (2008).
153. + Channels in human endothelial cells: Modulation of vascular endothelial growth factor (VEGF) signaling. J Biol Chem 2011; 286(19): 16846-16860.
154. Antoniotti S, FiorioPla A, Pregnolato S, Mottola A, Lovisolo D, Munaron L. Control of endothelial cell proliferation by calcium influx and arachidonic acid metabolism: A pharmacological approach. J Cell Physiol 2003; 197(3): 370-378.
155. Kohn, E.C., Liotta, L.A., Felder, C.C. Signal transduction inhibitor compounds. US5359078 (1994).
156. Hussain MM, Kotz H, Minasian L, Premkumar A, Sarosy G, Reed E, et al. Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer. J Clin Oncol 2003; 21(23): 4356-4363.
157. Kohn EC, Felder CC, Jacobs W, Holmes KA, Day A, Freer R, et al. Structure-function analysis of signal and growth inhibition by carboxyamido-triazole, CAI. Cancer Res 1994; 54(4): 935-942.
158. Oliver VK, Patton AM, Desai S, Lorang D, Libutti SK, Kohn EC. Regulation of the pro-angiogenic microenvironment by carboxyamido-triazole. J Cell Physiol 2003; 197(1): 139-148.
159. Bauer KS, Cude KJ, Dixon SC, Kruger EA, Figg WD. Carboxyamido-triazole inhibits angiogenesis by blocking the calcium-mediated nitric-oxide synthase-vascular endothelial growth factor pathway. J Pharmacol Exp Ther 2000; 292(1): 31-37.
160. Mikkelsen T, Lush R, Grossman SA, Carson KA, Fisher JD, Alavi JB, et al. Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiforme. Invest New Drugs 2007; 25(3): 259-263.
161. Mignen O, Brink C, Enfissi A, Nadkarni A, Shuttleworth TJ, Giovannucci DR, et al. Carboxyamidotriazole-induced inhibition of mitochondrial calcium import blocks capacitative calcium entry and cell proliferation in HEK-293 cells. J Cell Sci 2005; 118(Pt 23): 5615-5623.
162. Gaudet R. Divide and conquer: High resolution structural information on TRP channel fragments. J Gen Physiol 2009; 133(3): 231-237.
163. Gaudet R. TRP channels entering the structural era. J Physiol 2008; 586(Pt 15): 3565-3575.